- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07941635
Effects of Short-Term High-Concentration Formaldehyde Exposure on Respiratory Microecology and Inflammatory Markers in Healthy Adults (FORM-Resp)
Prospective Self-Control Study on the Effects of Short-Term High-Concentration Formaldehyde Exposure on Respiratory Microecology and Inflammatory Markers in Healthy Adults
Formaldehyde exposure is common in some occupational environments, including anatomy laboratories, and may affect respiratory health. However, the early biological changes caused by short-term high-concentration formaldehyde exposure remain unclear.
This prospective self-controlled observational study aims to evaluate the effects of short-term high-concentration formaldehyde exposure on respiratory microecology, inflammatory biomarkers, and acute respiratory symptoms in healthy adults. Participants will be monitored before and after formaldehyde exposure, and changes in airway-related biological indicators will be assessed through biological samples and clinical evaluations.
The findings of this study may provide human evidence for exposure control, ventilation improvement, protective measures, and health risk assessment in environments with formaldehyde exposure.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a prospective self-controlled observational study designed to investigate early respiratory biological responses associated with short-term high-concentration formaldehyde exposure in healthy adults.
Participants will be healthy medical students who enter an anatomy laboratory and experience short-term formaldehyde exposure during anatomy training. Each participant will serve as his or her own control. Biological samples and clinical information will be collected at multiple time points, including before exposure (T0), 6 hours after exposure (T1), and 24 hours after exposure (T2).
The study will evaluate changes in respiratory microecological composition, local inflammatory responses, systemic inflammatory and oxidative stress-related biomarkers, and acute irritation symptoms after formaldehyde exposure. Formaldehyde exposure levels, exposure duration, and protective measures will also be recorded to explore the relationship between exposure intensity and biological responses.
At T0, baseline information, respiratory symptoms, induced sputum samples, peripheral blood samples, and other relevant assessments will be collected. During and after exposure, environmental formaldehyde concentrations and exposure-related information will be monitored. At T1 and T2, repeated assessments will be performed, including symptom evaluation, induced sputum collection, peripheral blood collection, inflammatory biomarker detection, and respiratory microecological analysis.
This study aims to provide human-based evidence regarding early respiratory effects of short-term formaldehyde exposure and may contribute to improving ventilation strategies, occupational protection measures, exposure duration control, and health risk assessment in formaldehyde-exposed environments.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Locations
-
-
Zhejiang
-
Ningbo, Zhejiang, China, 315211
- Wang Changlai Building, East Campus, Ningbo University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Healthy adult medical students who attend anatomy laboratory courses involving short-term formaldehyde exposure will be recruited. Participants will undergo prospective self-controlled observation before and after exposure. Changes in respiratory microbiome composition, airway inflammatory biomarkers, systemic inflammatory and oxidative stress indicators, and acute irritation symptoms after formaldehyde exposure will be evaluated.
Description
Inclusion Criteria:
-
1: Aged 18-35 years old
2: The healthy medical students who participated in the anatomy course for the first time had no systematic formaldehyde / formalin occupational or teaching exposure in the past 6 months.
3: Health examination, and no history of chronic respiratory diseases ( such as asthma, active allergic rhinitis, chronic sinusitis, bronchiectasis, interstitial pulmonary fibrosis, etc. )
4: There were no acute upper respiratory tract infection, fever, COVID-19 or influenza-like symptoms in the past 4 weeks.
5: There was no use of antibiotics, glucocorticoids, bronchodilators, and immunomodulatory drugs in the past 4 weeks.
6: There was no obvious eye, nose, throat irritation or lower respiratory symptoms at baseline, and was able to cooperate with the completion of three induced sputum, two peripheral blood collections and related follow-up evaluations
7: Voluntary to participate in and sign a written informed consent.
Exclusion Criteria:
-
1: Have asthma, COPD, bronchiectasis, interstitial lung disease, chronic sinusitis, active allergic rhinitis or other chronic airway inflammatory diseases
2: Acute upper respiratory tract infection, fever, COVID-19 or influenza-like symptoms, or active allergies / obvious seasonal allergies occurred in the past 4 weeks
3: Used antibiotics, systemic or inhaled corticosteroids, bronchodilators, immunomodulatory drugs in the past 4 weeks
4: Current smoking, use of e-cigarettes or hookah, smoking history in the past six months, or obvious high exposure to second-hand smoke in the past four weeks
5: Exposure to non-daily formaldehyde, formalin or other strong irritant chemicals in the past 4 weeks
6: Have a clear history of allergy to formaldehyde or other chemicals, or intolerance to hypertonic saline atomization
7: Pregnant or lactating women
8: Severe cardiovascular and cerebrovascular diseases, coagulation dysfunction, recent hemoptysis, severe hypertension, recent ophthalmic surgery, epilepsy requiring drug treatment, severe arrhythmia or other conditions not suitable for induced sputum operation
9: All follow-ups and biological sample collections could not be completed for personal reasons, or researchers considered it inappropriate to continue participating in the study
Study Plan
How is the study designed?
Design Details
- Observational Models: COHORT
- Time Perspectives: RETROSPECTIVE
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Formaldehyde Exposure Cohort
Healthy adults receiving anatomy laboratory courses were enrolled in this prospective self-controlled observational study. Participants were exposed to short-term formaldehyde released from fixed tissue specimens in the anatomy laboratory and were evaluated before and after exposure. |
Short-term high-concentration formaldehyde exposure during anatomy laboratory courses |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change From Baseline in the Shannon Diversity Index of Induced Sputum Microbiota
Time Frame: Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure
|
The Shannon Diversity Index of induced sputum microbiota will be measured using 16S ribosomal ribonucleic acid gene sequencing. The index evaluates microbial alpha diversity by accounting for both taxon richness and evenness. It has a minimum value of 0 and no fixed maximum value, with higher values indicating greater microbial diversity. Change from baseline will be calculated as the value at each post-exposure time point minus the baseline value. |
Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change From Baseline in the Chao1 Richness Index of Induced Sputum Microbiota
Time Frame: Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure
|
The Chao1 Richness Index of induced sputum microbiota will be measured using 16S ribosomal ribonucleic acid gene sequencing. The index estimates the number of microbial taxa in a sample. It has a minimum value of 0 and no fixed maximum value, with higher values indicating greater estimated microbial richness. Change from baseline will be calculated as the value at each post-exposure time point minus the baseline value. |
Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure
|
|
R-Squared Value From Permutational Multivariate Analysis of Variance of Induced Sputum Microbial Community Structure Across Sampling Time Points
Time Frame: Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure
|
Beta diversity of induced sputum microbiota will be evaluated using principal coordinates analysis and permutational multivariate analysis of variance. The primary reported measure will be the R-squared value from the permutational multivariate analysis of variance, representing the proportion of variation in microbial community structure explained by sampling time. Values range from 0 to 1, with higher values indicating that sampling time explains a greater proportion of variation in microbial community structure. |
Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure
|
|
Change From Baseline in Induced Sputum Neutrophil Percentage
Time Frame: Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure
|
The percentage of neutrophils in induced sputum will be determined by differential cell counting of stained cytospin slides. Values range from 0% to 100%, with higher values indicating a greater proportion of neutrophils. Change from baseline will be calculated as the percentage at each post-exposure time point minus the baseline percentage and reported in percentage points. |
Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure
|
|
Change From Baseline in the Percentage of Neutrophils in Induced Sputum
Time Frame: Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure
|
The percentage of neutrophils in induced sputum will be determined by differential cell counting of stained cytospin slides. Values range from 0% to 100%, with higher values indicating a greater proportion of neutrophils. Change from baseline will be calculated as the percentage at each post-exposure time point minus the baseline percentage. |
Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure
|
|
Change From Baseline in the Percentage of Macrophages and Monocytes in Induced Sputum
Time Frame: Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure
|
The percentage of macrophages and monocytes in induced sputum will be determined by differential cell counting of stained cytospin slides. Values range from 0% to 100%, with higher values indicating a greater proportion of macrophages and monocytes. Change from baseline will be calculated as the percentage at each post-exposure time point minus the baseline percentage. |
Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure
|
|
Change From Baseline in the Percentage of Lymphocytes in Induced Sputum
Time Frame: Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure
|
The percentage of lymphocytes in induced sputum will be determined by differential cell counting of stained cytospin slides. Values range from 0% to 100%, with higher values indicating a greater proportion of lymphocytes. Change from baseline will be calculated as the percentage at each post-exposure time point minus the baseline percentage. |
Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure
|
|
Change From Baseline in the Percentage of Eosinophils in Induced Sputum
Time Frame: Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure
|
The percentage of eosinophils in induced sputum will be determined by differential cell counting of stained cytospin slides. Values range from 0% to 100%, with higher values indicating a greater proportion of eosinophils. Change from baseline will be calculated as the percentage at each post-exposure time point minus the baseline percentage. |
Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure
|
|
Change From Baseline in the Percentage of Bronchial Epithelial Cells in Induced Sputum
Time Frame: Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure
|
The percentage of bronchial epithelial cells in induced sputum will be determined by differential cell counting of stained cytospin slides. Values range from 0% to 100%, with higher values indicating a greater proportion of bronchial epithelial cells. Change from baseline will be calculated as the percentage at each post-exposure time point minus the baseline percentage. |
Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure
|
|
Change From Baseline in Interleukin 1 Beta Concentration in Induced Sputum Supernatant
Time Frame: Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure
|
Interleukin 1 beta concentration will be measured in induced sputum supernatant. Change from baseline will be calculated as the concentration at each post-exposure time point minus the baseline concentration. |
Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure
|
|
Change From Baseline in Interleukin 6 Concentration in Induced Sputum Supernatant
Time Frame: Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure
|
Interleukin 6 concentration will be measured in induced sputum supernatant. Change from baseline will be calculated as the concentration at each post-exposure time point minus the baseline concentration. |
Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure
|
|
Change From Baseline in Interleukin 8 Concentration in Induced Sputum Supernatant
Time Frame: Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure
|
Interleukin 8 concentration will be measured in induced sputum supernatant. Change from baseline will be calculated as the concentration at each post-exposure time point minus the baseline concentration. |
Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure
|
|
Change From Baseline in Tumor Necrosis Factor Alpha Concentration in Induced Sputum Supernatant
Time Frame: Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure
|
Tumor necrosis factor alpha concentration will be measured in induced sputum supernatant. Change from baseline will be calculated as the concentration at each post-exposure time point minus the baseline concentration |
Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure
|
|
Change From Baseline in C-Reactive Protein Concentration in Peripheral Blood
Time Frame: Baseline within 48 hours before exposure and 24 hours plus or minus 1 hour after exposure
|
C-reactive protein concentration will be measured in peripheral blood. Change from baseline will be calculated as the concentration 24 hours after exposure minus the baseline concentration. |
Baseline within 48 hours before exposure and 24 hours plus or minus 1 hour after exposure
|
|
Change From Baseline in Interleukin 6 Concentration in Peripheral Blood
Time Frame: Baseline within 48 hours before exposure and 24 hours plus or minus 1 hour after exposure
|
Interleukin 6 concentration will be measured in peripheral blood. Change from baseline will be calculated as the concentration 24 hours after exposure minus the baseline concentration. |
Baseline within 48 hours before exposure and 24 hours plus or minus 1 hour after exposure
|
|
Change From Baseline in Tumor Necrosis Factor Alpha Concentration in Peripheral Blood
Time Frame: Baseline within 48 hours before exposure and 24 hours plus or minus 1 hour after exposure
|
Tumor necrosis factor alpha concentration will be measured in peripheral blood. Change from baseline will be calculated as the concentration 24 hours after exposure minus the baseline concentration. |
Baseline within 48 hours before exposure and 24 hours plus or minus 1 hour after exposure
|
|
Change From Baseline in Malondialdehyde Concentration in Peripheral Blood
Time Frame: Baseline within 48 hours before exposure and 24 hours plus or minus 1 hour after exposure
|
Malondialdehyde concentration will be measured in peripheral blood as a marker of oxidative stress. Change from baseline will be calculated as the concentration 24 hours after exposure minus the baseline concentration. |
Baseline within 48 hours before exposure and 24 hours plus or minus 1 hour after exposure
|
|
Change From Baseline in Eye Irritation Score Assessed Using a Visual Analog Scale
Time Frame: Baseline within 48 hours before exposure, immediately after exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure
|
Eye irritation will be rated by each participant using a visual analog scale ranging from 0 to 10, where 0 indicates no symptoms and 10 indicates the most severe symptoms imaginable. Higher scores indicate greater symptom severity. Change from baseline will be calculated as the score at each post-exposure assessment minus the baseline score. |
Baseline within 48 hours before exposure, immediately after exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure
|
|
Change From Baseline in Nasal Irritation Score Assessed Using a Visual Analog Scale
Time Frame: Baseline within 48 hours before exposure, immediately after exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure
|
Nasal irritation will be rated by each participant using a visual analog scale ranging from 0 to 10, where 0 indicates no symptoms and 10 indicates the most severe symptoms imaginable. Higher scores indicate greater symptom severity. Change from baseline will be calculated as the score at each post-exposure assessment minus the baseline score. |
Baseline within 48 hours before exposure, immediately after exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure
|
|
Change From Baseline in Throat Irritation Score Assessed Using a Visual Analog Scale
Time Frame: Baseline within 48 hours before exposure, immediately after exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure
|
Throat irritation will be rated by each participant using a visual analog scale ranging from 0 to 10, where 0 indicates no symptoms and 10 indicates the most severe symptoms imaginable. Higher scores indicate greater symptom severity. Change from baseline will be calculated as the score at each post-exposure assessment minus the baseline score. |
Baseline within 48 hours before exposure, immediately after exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure
|
|
Change From Baseline in Cough Score Assessed Using a Visual Analog Scale
Time Frame: Baseline within 48 hours before exposure, immediately after exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure
|
Cough will be rated by each participant using a visual analog scale ranging from 0 to 10, where 0 indicates no symptoms and 10 indicates the most severe symptoms imaginable. Higher scores indicate greater symptom severity. Change from baseline will be calculated as the score at each post-exposure assessment minus the baseline score. |
Baseline within 48 hours before exposure, immediately after exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure
|
|
Change From Baseline in Chest Tightness Score Assessed Using a Visual Analog Scale
Time Frame: Baseline within 48 hours before exposure, immediately after exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure
|
Chest tightness will be rated by each participant using a visual analog scale ranging from 0 to 10, where 0 indicates no symptoms and 10 indicates the most severe symptoms imaginable. Higher scores indicate greater symptom severity. Change from baseline will be calculated as the score at each post-exposure assessment minus the baseline score. |
Baseline within 48 hours before exposure, immediately after exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure
|
Collaborators and Investigators
Investigators
- Principal Investigator: Chao Cao, Ningbo University Affiliated First Hospital
Publications and helpful links
General Publications
- Catalani S, Donato F, Madeo E, Apostoli P, De Palma G, Pira E, Mundt KA, Boffetta P. Occupational exposure to formaldehyde and risk of non hodgkin lymphoma: a meta-analysis. BMC Cancer. 2019 Dec 23;19(1):1245. doi: 10.1186/s12885-019-6445-z.
- Schwilk E, Zhang L, Smith MT, Smith AH, Steinmaus C. Formaldehyde and leukemia: an updated meta-analysis and evaluation of bias. J Occup Environ Med. 2010 Sep;52(9):878-86. doi: 10.1097/JOM.0b013e3181ef7e31.
- Kang DS, Kim HS, Jung JH, Lee CM, Ahn YS, Seo YR. Formaldehyde exposure and leukemia risk: a comprehensive review and network-based toxicogenomic approach. Genes Environ. 2021 Apr 12;43(1):13. doi: 10.1186/s41021-021-00183-5.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2026-R311-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
The plan for sharing individual participant data (IPD) has not yet been determined. Any future data sharing will be considered in accordance with ethical requirements, participant privacy protection, and institutional policies.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.